Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

Attrition Rates and Incidence of Mental Health Disorders in an Attention-Deficit/Hyperactivity Disorder (ADHD) Cohort, Active Component, U.S. Armed Forces, 2014–2018

Image of 1_Soldier at medical screening. Capt. Michelle Tsai, the behavioral health officer for the 4th Brigade, 2nd Infantry Division, reviews medical information in her office at the Joint Readiness Training Center June 17. Tsai, an Alexandria, Va., native, is here with the Raider Brigade in support of training operations for the unit's upcoming deployment to Iraq. (Photo by Pfc. Luke Rollins)

What Are the New Findings?

The majority of new military accessions in 2014 with documented ADHD diagnoses within their first year of service were not detected during their MEPS screening physical exam (64.8%), suggesting many new accessions do not disclose previous ADHD diagnoses during enlistment. New accessions in 2014 with ADHD diagnoses who received a prescription for ADHD medication started medication quickly (91.0% within 6 months) and had higher rates of attrition from service and higher incidence rates of comorbid mental health disorders than their untreated ADHD counterparts.

What Is the Impact on Readiness and Force Health Protection?

Due to its high prevalence in the U.S. general population, ADHD impacts the pool of military applicants. Future changes to enlistment standards should consider how to optimize or incentivize applicant disclosure of a pre-existing ADHD diagnosis during MEPS screening or service specific medical waiver review and discourage withholding an ADHD diagnosis during enlistment.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common childhood diagnosis and affects the pool of potential military applicants. Early detection and treatment of ADHD may decrease the risk of developing comorbidities; however, accession policy in place during this study period (2014–2018) disqualified applicants who used ADHD medication for more than 24 months cumulative after age 14. The objective of this study was to assess attrition from military service in newly accessed active component service members diagnosed with ADHD as compared to controls. In addition, attrition rates and incidence rates of mental health diagnoses were assessed in service members with ADHD by treatment status (i.e., treated vs untreated ADHD) where treatment was defined as being dispensed an FDA-approved ADHD medication at least twice within 181 days. Almost two-thirds (64.8%) of newly accessed ADHD cases in 2014 were identified after enlistment medical screening at Military Entrance Processing Stations (MEPS) (i.e., post-MEPS). These post-MEPS ADHD cases accounted for 99.1% of the treated ADHD cases. The vast majority of treated cases (91.0%) were dispensed ADHD medication within 6 months of accession. The treated ADHD group had higher rates of attrition and incidence of mental health disorders during the follow-up period. These study findings highlight the problem of nondisclosure of ADHD among military applicants. Future changes to enlistment standards should consider the optimal way to promote applicant disclosure of ADHD during MEPS screening or for medical waiver review and should discourage withholding an ADHD diagnosis during enlistment.

Background

Attention-deficit/hyperactivity disorder (ADHD) is a common diagnosis in childhood, characterized by persistent impairing inattention, hyperactivity, and impulsivity. Symptoms are usually recognized in patients before the age of 12.1 Estimates for the prevalence of ADHD in U.S. children 2–17 years old range from 9–11% while adult ADHD prevalence in the U.S. is estimated at 4.4%.2 Medication has become a mainstay of treatment with U.S. surveillance data indicating that 62% of children with ADHD in 2016 took medication.3 ADHD patients frequently have comorbid conditions such as mood, anxiety, and substance use disorders,2,4–6 but early ADHD treatment with medication may convey some protection against these co-occurring conditions.7–9

Due to its high prevalence in the adolescent and adult population, ADHD has readiness and force health impacts on the Department of Defense (DOD) and affects the pool of military applicants.7 During 2000–2018, the prevalence rate of ADHD in the DOD ranged between 1.7% and 3.9% and has steadily declined since 2011 (E. T.Reeves, MD, unpublished data, 2017). Current DOD accession policy, DOD Instruction (DODI) 6130.03 (updated in 2018), disqualifies military applicants with diagnosed ADHD if they meet any of the following conditions: 1) had ADHD medication prescribed in the previous 24 months; 2) had an educational plan or work accommodation after 14 years of age; 3) had a history of comorbid mental health disorders; 4) had documentation of adverse academic, occupational, or work performance.10 The previous updates to DOD accession policy occurred in 2010 and 2005 and disqualified applicants who used ADHD medication for more than 24 months cumulative after the age of 14 years and if there had been medication use in the previous 12 months, respectively.11 The policy change trends have extended the time period that ADHD-diagnosed accessions to the military had to be without prescribed ADHD medication. Comparing annual rates in 2006–2010 to 2011–2017, this policy change was associated with increased waiver submissions for ADHD (mean of 560/year vs 789/year) and percent applicant disqualifications (36.4%/ year vs 46.9%/year) (Figure 1).12 In 2017, ADHD and disruptive behavior disorders were the fifth most frequent diagnoses resulting in medical disqualification of first-time enlisted active component military applicants (this study's surveillance period was from Jan. 2014 through Dec. 2018).12 A previous study evaluated ADHD accessions through waiver admissions to the Army and found no change in retention rates; however, that study was conducted well before the current accession policy was in place.7 Other studies have assessed ADHD and its association with PTSD,4,6 but no surveillance data have been published on new accession active component service members with ADHD and the effect of medication treatment.

The current study provides evidence-based data relevant to the DOD's medical accession policy. The main objective of this study was to assess attrition from military service in active component service members diagnosed with ADHD compared to matched controls without ADHD. In addition, attrition rates were assessed for service members with ADHD by treatment status. Finally, incidence rates of selected mental health disorder diagnoses were compared between service members with ADHD who were prescribed medication for ADHD and those who were not.

Methods

This study utilized a retrospective cohort design. The surveillance period was 1 Jan. 2014 through 31 Dec. 2018. The surveillance population included any member of the Army, Navy, Air Force, or Marine Corps who first entered military service in 2014. All data used to identify prevalent cases of ADHD were derived from records routinely maintained in the Defense Medical Surveillance System (DMSS), which is maintained by the Armed Forces Health Surveillance Division (AFHSD). The DMSS includes medical encounter data (e.g. outpatient visits, hospitalizations) of active component members of the U.S. Armed Forces in military and civilian (if reimbursed through the Military Health System) treatment facilities. The DMSS also includes medical screening data from Military Entrance Processing stations (MEPS) and records of prescribed and dispensed medications from the Pharmacy Data Transaction Service (PDTS) which were also used in this analysis.

For surveillance purposes, an ADHD case was defined as a service member with a qualifying ADHD diagnosis in the first or second diagnostic position for diagnoses assigned during a MEPS medical screening; or 1 hospitalization with any of the qualifying diagnoses of ADHD in the first or second diagnostic position; or 2 outpatient medical encounters within 180 days of each other, with any of the defining diagnoses of ADHD in the specialty care setting, identified by Medical Expense and Performance Reporting System (MEPRS) code beginning with 'BF'. The International Classification of Diseases, 9th Revision (ICD-9) and International Classification of Diseases, 10th Revision (ICD-10) codes used to identify ADHD cases included all those falling under the parent codes 314 and F90, respectively. Because the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) requires the presence of symptoms prior to age 12 to meet the diagnostic criteria for ADHD, individuals with a diagnosis of ADHD in 2014 were considered to be prevalent cases that existed at the time of accession regardless of when they were formally diagnosed.1

All active component service members who entered military service in 2014 and were found to have ADHD diagnoses during a MEPS medical screening or who met the case definition for a new ADHD diagnosis during 2014 were identified. Service members within this cohort were then further classified into 2 groups: ADHD cases that were treated with ADHD medication and ADHD cases who were not treated with ADHD medication.

To qualify as treated, service members had to have pharmacy documentation of being dispensed an FDA licensed drug for the treatment of ADHD at least twice within 6 months (181 days); this criterion is consistent with that employed in previous studies of ADHD medication use.9 Qualifying ADHD medications included stimulants (amphetamines, methylphenidates), guanfacine (Intuniv), clonidine (Kapvay), and atomoxetine (Strattera). Active component service members dispensed ADHD medication with longer gaps than this threshold were classified as untreated. Because a service member could be admitted to the cohort at any time in 2014, pharmacy data through the first 180 days of 2015 were included in the analysis.

The control group consisted of active component service members without ADHD and matched 1:1 (i.e., case control ratio was 1:1) on age, gender, and date of accession (within 30 days of each ADHD case). Exclusion criteria included a diagnosis of depression, anxiety, or substance-related disorder at accession as documented in the MEPS record or a documented ADHD diagnosis prior to 2014.

The follow-up period for each cohort member and his or her matched control began at 181 days after their initial entry date into service. To assess attrition from service, individuals in each group were followed until 31 Dec. 2018 or until the service member left active service or died. To determine the incidence of mental health disorders, service members were followed until 31 Dec. 2018 or until the service member left active service, died, or received 1 or more of the mental health diagnoses of interest as defined below. To assess attrition, length of service was calculated by summing the number of days a service member was in service.

Occurrences of depressive, anxiety, alcohol- and/or substance-related disorders were ascertained by applying standard AFHSD case definitions.13 Depressive, anxiety, alcohol- or substance-related disorders were all respectively defined as 1 hospitalization with any of the defining diagnoses (see AFHSD case definitions for full ICD-9 and ICD-10 code lists for each disorder) in the first or second diagnostic position; or 2 outpatient medical encounters, within 180 days of each other, with any of the defining diagnoses in the first or second diagnostic position; or 1 outpatient medical encounter in a psychiatric or mental health care specialty setting, defined by MEPRS code 'BF', with any of the defining diagnoses in the first or second diagnostic position. Service members who received a qualifying mental health disorder diagnosis were associated with the treated ADHD group only if the service member had been dispensed ADHD medication at least 30 days prior to the diagnosis of depressive, anxiety, alcohol- or substance-related disorder (Figure 2).

Descriptive statistics were used to characterize service members in the 3 groups (control without ADHD, ADHD only, and ADHD with medication) who entered the military and were newly diagnosed with ADHD in 2014. The groups were compared on several background variables (i.e., sex, age group, race/ethnicity group, branch of service, and rank/grade) using chi-square tests. To compare the incidence of depressive, anxiety, alcohol- and substance-related disorders diagnosed in these groups, crude incidence rates and their associated 95% confidence intervals were calculated. Finally, Kaplan-Meier curves and the log-rank test were used to examine attrition rates in the study groups over time. All analyses were conducted using SAS/STAT software, version 9.4 (2014, SAS Institute, Cary, NC).

Results

A total of 996 service members who were newly accessed into the military in 2014 and qualified as an ADHD case were identified. Of the ADHD cases identified, 334 were classified as treated with ADHD medication and 662 were classified as untreated. Compared to the untreated ADHD group, the treated group had relatively higher proportions of females, service members aged 20 years or older, members of racial/ethnic minority groups, Army members, and junior officers. The untreated ADHD group had relatively higher proportions of Navy, Marine Corps, and Air Force members compared to the treated ADHD group (Table 1).

The initial attrition rates in the total ADHD cohort (treated and untreated ADHD groups) and the control group are illustrated in Figure 3. Nearly 40% of ADHD cases left service within the first 6 months of the surveillance period. Since these individuals left the military in less than 6 months, they did not have the opportunity to be a treated ADHD case as defined in this study (dispensed medication at least twice within 6 months). Thus, an additional exclusion was applied for people who did not remain in the military for at least 6 months.

After applying the requirement that service members remained in the military at least 6 months, the ADHD group decreased to 616 individuals (331 treated with medication and 285 untreated), and the non-ADHD (control) group decreased to 911 (Table 1). The relative proportions within the covariates remained similar with the exception of the proportion of untreated service members in the Navy which decreased from 53% (n=296) to 12% (n=35) (Table 1). Although the large initial drop of service members did not remain after applying the requirement for at least 6-months of service, attrition curves comparing ADHD (combined treated and untreated) and non-ADHD groups and treated ADHD, untreated ADHD, and non-ADHD groups were clearly different. The treated ADHD cohort had the highest attrition rates among these groups (Figures 4, 5).

ADHD cases were analyzed according to whether they were detected during MEPS screening encounters or after accession (non-MEPS encounter) (Table 2). Only 35.2% of the ADHD cases were identified with MEPS screening. Almost all of the treated ADHD cohort (328 of 331) were first documented after MEPS, and 91.0% of treated ADHD cases started medication within 6 months of accession. The 3 ADHD cases who were identified during MEPS screening and who went on to start medication during the surveillance period were first dispensed medication over 2 years after accession.

Compared to untreated ADHD and non-ADHD groups, the treated ADHD group had significantly higher crude incidence rates of all mental health disorders with the highest rate observed for anxiety disorders (an individual service member could have had multiple mental health disorders). The untreated ADHD cohort's incidence rates of mental health disorders were not statistically significantly different from the rates among those in the non-ADHD group (Table 3).

Editorial Comment

This report describes accessions to the military in 2014 with documented ADHD in the same year to examine the impact of the military ADHD enlistment standards in place at that time. Nearly two-thirds of the new accession ADHD cases detected in the first year of service in 2014 were identified after accession and after the MEPS screening process. Service members with treated ADHD (99.1% of whom were diagnosed after the MEPS screening process) started medications quickly with 91.0% having had drugs prescribed within 6 months of accession. This finding suggests that most treated ADHD cases identified in this study withheld their ADHD diagnosis at accession and then quickly sought treatment after completing basic training. The treated ADHD group had the highest attrition rates over the 5-year surveillance period compared to untreated ADHD and non-ADHD groups and had crude higher incidence rates of mental health disorders.

The ADHD accession policy selects less severe and higher functioning ADHD individuals, but nondisclosure of medical conditions, particularly behavioral health diagnoses, is a difficult problem for accession medical screening to resolve. Previous studies have discussed the problem that more recruits are dismissed annually for withholding an ADHD diagnosis than applicants who are truthful in disclosing the diagnosis.7 Results of the current study suggest the persistence of this problem, even after multiple policy changes over the past 2 decades. Future changes to enlistment standards should consider how to optimize or incentivize applicant disclosure of ADHD during MEPS screening or for medical waiver review as well as discourage withholding an ADHD diagnosis during enlistment. Potential ways to encourage disclosing ADHD in military applicants could involve different ADHD standards based on a new accession's occupation (difficult to do with MEPS screening as an occupation may not be defined at that time) or emphasizing more relaxed standards with service-based medical waivers after a thorough review and interview with the enlistee. At the same time, nondisclosure of ADHD should be descentivised with the threat of disqualification from service or other punishment. Additional studies examining ADHD's impact on military readiness, deployment health, and different occupations would help advance and inform accession decisions regarding future ADHD standards.

This is the first study to assess medication dispensed for ADHD in new active component accessions since ADHD enlistment standards were updated in 2010. In addition, this study uses multiple sources of data available in the DMSS which allow for a longitudinal analysis and provide analytic evidence that may inform accession policies in the future.

Multiple limitations to this study should be considered. This analysis used data from PDTS which identified whether ADHD medications had been dispensed to active component service members with ADHD diagnoses. However, these data cannot be used to assess the medication adherence of these patients. Furthermore, patients with ADHD in this study could be prescribed ADHD medications for other medical conditions (FDA-approved indications or off-label use) or obtain ADHD medications by other means without a prescription. In addition, the population of patients who were dispensed ADHD medication could be different (e.g., have more severe symptoms or comorbid conditions) from the population of ADHD patients who were not dispensed medication. ADHD diagnosis data were derived from ICD-9 and ICD-10 coded medical encounters or from the MEPS tables according to standardized health surveillance case definitions which could underestimate the prevalence of ADHD, especially in service members not actively being treated with medication for ADHD or withholding information at MEPS assessment (misclassification bias).

The DOD must continue to evaluate its accession policies related to ADHD, since the condition impacts the military enlistment pool. The observation of potentially undisclosed ADHD cases with worse outcomes in this study illustrates problems and challenges for the military when recruits do not truthfully reveal a previous ADHD diagnosis. Additional studies could further explore the issues identified in this analysis related to ADHD in new accessions and contribute to the enhanced readiness of service members with ADHD.

Author Affiliations: Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland (Maj Sayers); Defense Health Agency, Armed Forces Health Surveillance Division (Ms. Zhu, Dr. Clark).

Disclaimer: The views expressed herein are those of the authors and do not necessarily reflect official policy or position of Uniformed Services University of the Health Sciences, the Department of Defense, or Departments of the Army, Navy, or Air Force.

References

  1. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed (DSM-5). Arlington, VA: American Psychiatric Association; 2013.
  2. Centers for Disease Control and Prevention. Data and Statistics About ADHD. https://www.cdc.gov/ncbddd/adhd/data.html. Accessed 5 Sept. 2019.
  3. Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among US children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212. 
  4. Howlett JR, Campbell-Sills L, Jain S, et al. Attention deficit hyperactivity disorder and risk of posttraumatic stress and related disorders: A prospective longitudinal evaluation in US Army soldiers. J Trauma Stress. 2018;31(6):909–918.
  5. Spencer AE, Faraone SV, Bogucki OE, et al. Examining the association between posttraumatic stress disorder and attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2016; 77(1):72–83. 
  6. Ivanov I, Yehuda R. Optimizing fitness for duty and post-combat clinical services for military personnel and combat veterans with ADHD—a
  7. Krauss MR, Russell RK, Powers TE, Li L. Accession standards for attention-deficit/hyperactivity disorder: a survival analysis of military recruits, 1995–2000. Mil Med. 2006;171(2):99–102.
  8. Biederman J, DiSalvo M, Fried R, Woodworth KY, Biederman I, Faraone SV. Quantifying the protective effects of stimulants on functional outcomes in attention-deficit/hyperactivity disorder: A focus on number needed to treat statistic and sex effects. J Adolesc Health. 2019;65(6):784–789.
  9. Chang Z, D’Onofrio BM, Quinn PD, Lichtenstein P, Larsson H. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry. 2016;80(12):916–922.
  10. Office of the Under Secretary of Defense for Personnel and Readiness. Department of Defense Instruction 6130.03. Medical Standards for Appointment, Enlistment, or Induction in the Military Services. 6 May 2018. 
  11. Office of the Under Secretary of Defense for Personnel and Readiness. Department of Defense Instruction 6130.03. Medical Standards for Appointment, Enlistment, or Induction in the Military Services. 28 April 2010.
  12. Department of Defense. Accession Medical Standards Analysis & Research Activity, Annual Report 2018. Silver Spring, MD: Statistics and Epidemiology Branch, Walter Reed Army Institute of Research; 2018.
  13. Armed Forces Health Surveillance Branch. https://www.health.mil/Military-Health-Topics/Combat-Support/Armed-Forces-Health-Surveillance-Branch/Epidemiology-and-Analysis/Surveillance-Case-Definitions. Accessed 6 Sept. 2019.

FIGURE 1. Annual ADHD waivers and approvals with total DOD annual accessions, 2006–2017

FIGURE 2. Classifying mental health disorders as treated or untreated ADHD cases

FIGURE 3. Attrition by cohort for active component service members who accessed the service in 2014, comparing those with ADHD 2014 diagnoses and a matched control group without ADHD, 2014–2018

FIGURE 4. Attrition by cohort for active component service members who accessed the service in 2014 and remained in the service for at least 6 months, comparing those with ADHD 2014 diagnoses and a matched control group without ADHD, 2014–2018

FIGURE 5. Attrition by cohort for active component service members who accessed the service in 2014 and remained in the service for at least 6 months, comparing those with ADHD 2014 diagnoses who did and did not receive specific treatment with a matched control group without ADHD, 2014–2018

TABLE 1. Demographic and military characteristics of treated and untreated ADHD cases in active component military members who entered service during calendar year 2014

TABLE 2. Service members identified as ADHD cases stratified by identification at MEPS screening vs identification after military accession and by time to starting ADHD medication

TABLE 3. Incidence rates of mental health disorders in treated versus untreated ADHD cases

You also may be interested in...

Absolute and relative morbidity burdens attributable to various illnesses and injuries, active component, U.S. Armed Forces, 2018

Article
5/1/2019
Cover 1

In 2018, mental health disorders accounted for the largest proportions of the morbidity and healthcare burdens that affected the pediatric and younger adult beneficiary age groups. Among adults aged 45–64 years, musculoskeletal diseases accounted for the most morbidity and healthcare burdens, and among adults aged 65 years or older, cardiovascular diseases accounted for the most.

Absolute and relative morbidity burdens attributable to various illnesses and injuries, non-service member beneficiaries of the Military Health System, 2018

Article
5/1/2019
Cover 4

In 2018, mental health disorders accounted for the largest proportions of the morbidity and healthcare burdens that affected the pediatric and younger adult beneficiary age groups. Among adults aged 45–64 years, musculoskeletal diseases accounted for the most morbidity and health care burdens, and among adults aged 65 years or older, cardiovascular diseases accounted for the most.

Incidence, Timing, and Seasonal Patterns of Heat Illnesses During U.S. Army Basic Combat Training, 2014–2018

Article
4/1/2019
U.S. Marines participate in morning physical training during a field exercise at Marine Corps Base Camp Pendleton, California. (Photo Courtesy: U.S. Marine Corps)

Risk factors for heat illnesses (HIs) among new soldiers include exercise intensity, environmental conditions at the time of exercise, a high body mass index, and conducting initial entry training during hot and humid weather when recruits are not yet acclimated to physical exertion in heat. This study used data from the Defense Health Agency’s–Weather-Related Injury Repository to calculate rates and to describe the incidence, timing, and geographic distribution of HIs among soldiers during U.S. Army basic combat training (BCT). From 2014 through 2018, HI events occurred in 1,210 trainees during BCT, resulting in an overall rate of 3.6 per 10,000 BCT person-weeks (p-wks) (95% CI: 3.4–3.8). HI rates (cases per 10,000 BCT p-wks) varied among the 4 Army BCT sites: Fort Benning, GA (6.8); Fort Jackson, SC (4.4); Fort Sill, OK (1.8); and Fort Leonard Wood, MO (1.7). Although the highest rates ofHIs occurred at Fort Benning, recruits in all geographic areas were at risk. The highest rates of HI occurred during the peak training months of June through Sept., and over half of all HI cases affected soldiers during the first 3 weeks of BCT. Prevention of HI among BCT soldiers requires relevant training of both recruits and cadre as well as the implementation of effective preventive measures.

Update: Exertional Rhabdomyolysis, Active Component, U.S. Armed Forces, 2014–2018

Article
4/1/2019
U.S. Marines sprint uphill during a field training exercise at Marine Corps Air Station Miramar, California. to maintain contact with an aviation combat element, teaching and sustaining their proficiency in setting up and maintaining communication equipment.  (Photo Courtesy: U.S. Marine Corps)

Among active component service members in 2018, there were 545 incident diagnoses of rhabdomyolysis likely due to exertional rhabdomyolysis, for an unadjusted incidence rate of 42.0 cases per 100,000 person-years. Subgroup-specific rates in 2018 were highest among males, those less than 20 years old, Asian/Pacific Islander service members, Marine Corps and Army members, and those in combat-specific or “other/unknown” occupations. During 2014–2018, crude rates of exertional rhabdomyolysis increased steadily from 2014 through 2016 after which rates declined slightly in 2017 before increasing again in 2018. Compared to service members in other race/ethnicity groups, the overall rate of exertional rhabdomyolysis was highest among non-Hispanic blacks in every year except 2018. Overall and annual rates were highest among Marine Corps members, intermediate among those in the Army, and lowest among those in the Air Force and Navy. Most cases of exertional rhabdomyolysis were diagnosed at installations that support basic combat/recruit training or major ground combat units of the Army or the Marine Corps. Medical care providers should consider exertional rhabdomyolysis in the differential diagnosis when service members (particularly recruits) present with muscular pain or swelling, limited range of motion, or the excretion of dark urine (possibly due to myoglobinuria) after strenuous physical activity, particularly in hot, humid weather.

Update: Heat Illness, Active Component, U.S. Armed Forces, 2018

Article
4/1/2019
Drink water the day before and during physical activity or if heat is going to become a factor. (Photo Courtesy: U.S. Air Force)

In 2018, there were 578 incident diagnoses of heat stroke and 2,214 incident diagnoses of heat exhaustion among active component service members. The overall crude incidence rates of heat stroke and heat exhaustion diagnoses were 0.45 cases and 1.71 cases per 1,000 person-years, respectively. In 2018, subgroup-specific rates of incident heat stroke diagnoses were highest among males and service members less than 20 years old, Asian/Pacific Islanders, Marine Corps and Army members, recruit trainees, and those in combat-specific occupations. Subgroup-specific incidence rates of heat exhaustion diagnoses in 2018 were notably higher among service members less than 20 years old, Asian/Pacific Islanders, Army and Marine Corps members, recruit trainees, and service members in combat-specific occupations. During 2014–2018, a total of 325 heat illnesses were documented among service members in Iraq and Afghanistan; 8.6% (n=28) were diagnosed as heat stroke. Commanders, small unit leaders, training cadre, and supporting medical personnel must ensure that the military members whom they supervise and support are informed about the risks, preventive countermeasures, early signs and symptoms, and first-responder actions related to heat illnesses.

Update: Exertional Hyponatremia, Active Component, U.S. Armed Forces, 2003–2018

Article
4/1/2019
Drink water the day before and during physical activity or if heat is going to become a factor. (Photo Courtesy: U.S. Air Force)

From 2003 through 2018, there were 1,579 incident diagnoses of exertional hyponatremia among active component service members, for a crude overall incidence rate of 7.2 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, females, those less than 20 years old, and recruit trainees had higher overall incidence rates of exertional hyponatremia diagnoses. The overall incidence rate during the 16-year period was highest in the Marine Corps, intermediate in the Army and Air Force, and lowest in the Navy. Overall rates during the surveillance period were highest among Asian/Pacific Islander and non-Hispanic white service members and lowest among non-Hispanic black service members. Between 2003 and 2018, crude annual incidence rates of exertional hyponatremia peaked in 2010 (12.7 per 100,000 p-yrs) and then decreased to 5.3 cases per 100,000 p-yrs in 2013 before increasing in 2014 and 2015. The crude annual rate in 2018 (6.3 per 100,000 p-yrs) represented a decrease of 26.5% from 2015. Service members and their supervisors must be knowledgeable of the dangers of excessive water consumption and the prescribed limits for water intake during prolonged physical activity (e.g., field training exercises, personal fitness training, and recreational activities) in hot, humid weather.

Modeling Lyme Disease Host Animal Habitat Suitability, West Point, New York

Article
4/1/2019
A deer basks in the morning sun at Joint Base San Antonio-Fort Sam Houston, Texas.  (Photo Courtesy: U.S. Air Force)

As the most frequently reported vector-borne disease among active component U.S. service members, with an incidence rate of 16 cases per 100,000 person-years in 2011, Lyme disease poses both a challenge to health care providers in the Military Health System and a threat to military readiness. Spread through the bite of an infected blacklegged tick, infection with the bacterial cause of Lyme disease can have lasting effects that may lead to medical discharge from the military. The U.S. Military Academy at West Point is situated in a highly endemic area in New York State. To identify probable areas where West Point cadets as well as active duty service members stationed at West Point and their families might contract Lyme disease, this study used Geographic Information System mapping methods and remote sensing data to replicate an established spatial model to identify the likely habitat of a key host animal—the white-tailed deer.

Brief Report: Male Infertility, Active Component, U.S. Armed Forces, 2013–2017

Article
3/1/2019
Sperm is the male reproductive cell  Photo: iStock

Infertility, defined as the inability to achieve a successful pregnancy after 1 year or more of unprotected sexual intercourse or therapeutic donor insemination, affects approximately 15% of all couples. Male infertility is diagnosed when, after testing both partners, reproductive problems have been found in the male. A male factor contributes in part or whole to about 50% of cases of infertility. However, determining the true prevalence of male infertility remains elusive, as most estimates are derived from couples seeking assistive reproductive technology in tertiary care or referral centers, population-based surveys, or high-risk occupational cohorts, all of which are likely to underestimate the prevalence of the condition in the general U.S. population.

Sexually Transmitted Infections, Active Component, U.S. Armed Forces, 2010–2018

Article
3/1/2019
Neisseria gonorrhoeae Photo Courtesy of CDC: M Rein

This report summarizes incidence rates of the 5 most common sexually transmitted infections (STIs) among active component service members of the U.S. Armed Forces during 2010–2018. Infections with chlamydia were the most common, followed in decreasing order of frequency by infections with genital human papillomavirus (HPV), gonorrhea, genital herpes simplex virus (HSV), and syphilis. Compared to men, women had higher rates of all STIs except for syphilis. In general, compared to their respective counterparts, younger service members, non-Hispanic blacks, soldiers, and enlisted members had higher incidence rates of STIs. During the latter half of the surveillance period, the incidence of chlamydia and gonorrhea increased among both male and female service members. Rates of syphilis increased for male service members but remained relatively stable among female service members. In contrast, the incidence of genital HPV and HSV decreased among both male and female service members. Similarities to and differences from the findings of the last MSMR update on STIs are discussed.

Vasectomy and Vasectomy Reversals, Active Component, U.S. Armed Forces, 2000–2017

Article
3/1/2019
Sperm is the male reproductive cell  Photo: iStock

During 2000–2017, a total of 170,878 active component service members underwent a first-occurring vasectomy, for a crude overall incidence rate of 8.6 cases per 1,000 person-years (p-yrs). Among the men who underwent incident vasectomy, 2.2% had another vasectomy performed during the surveillance period. Compared to their respective counterparts, the overall rates of vasectomy were highest among service men aged 30–39 years, non-Hispanic whites, married men, and those in pilot/air crew occupations. Male Air Force members had the highest overall incidence of vasectomy and men in the Marine Corps, the lowest. Crude annual vasectomy rates among service men increased slightly between 2000 and 2017. The largest increases in rates over the 18-year period occurred among service men aged 35–49 years and among men working as pilots/air crew. Among those who underwent vasectomy, 1.8% also had at least 1 vasectomy reversal during the surveillance period. The likelihood of vasectomy reversal decreased with advancing age. Non-Hispanic black and Hispanic service men were more likely than those of other race/ethnicity groups to undergo vasectomy reversals.

Testosterone Replacement Therapy Use Among Active Component Service Men, 2017

Article
3/1/2019
Testosterone

This analysis summarizes the prevalence of testosterone replacement therapy (TRT) during 2017 among active component service men by demographic and military characteristics. This analysis also determines the percentage of those receiving TRT in 2017 who had an indication for receiving TRT using the 2018 American Urological Association (AUA) clinical practice guidelines. In 2017, 5,093 of 1,076,633 active component service men filled a prescription for TRT, for a period prevalence of 4.7 per 1,000 male service members. After adjustment for covariates, the prevalence of TRT use remained highest among Army members, senior enlisted members, warrant officers, non-Hispanic whites, American Indians/Alaska Natives, those in combat arms occupations, healthcare workers, those who were married, and those with other/unknown marital status. Among active component male service members who received TRT in 2017, only 44.5% met the 2018 AUA clinical practice guidelines for receiving TRT.

Update: Malaria, U.S. Armed Forces, 2018

Article
2/1/2019
Anopheles merus

Malaria infection remains an important health threat to U.S. service mem­bers who are located in endemic areas because of long-term duty assign­ments, participation in shorter-term contingency operations, or personal travel. In 2018, a total of 58 service members were diagnosed with or reported to have malaria. This represents a 65.7% increase from the 35 cases identi­fied in 2017. The relatively low numbers of cases during 2012–2018 mainly reflect decreases in cases acquired in Afghanistan, a reduction due largely to the progressive withdrawal of U.S. forces from that country. The percentage of cases of malaria caused by unspecified agents (63.8%; n=37) in 2018 was the highest during any given year of the surveillance period. The percent­age of cases identified as having been caused by Plasmodium vivax (10.3%; n=6) in 2018 was the lowest observed during the 10-year surveillance period. The percentage of malaria cases attributed to P. falciparum (25.9 %) in 2018 was similar to that observed in 2017 (25.7%), although the number of cases increased. Malaria was diagnosed at or reported from 31 different medical facilities in the U.S., Afghanistan, Italy, Germany, Djibouti, and Korea. Pro­viders of medical care to military members should be knowledgeable of and vigilant for clinical manifestations of malaria outside of endemic areas.

Update: Incidence of Glaucoma Diagnoses, Active Component, U.S. Armed Forces, 2013–2017

Article
2/1/2019
Glaucoma

Glaucoma is an eye disease that involves progressive optic nerve damage and vision loss, leading to blindness if undetected or untreated. This report describes an analysis using the Defense Medical Surveillance System to identify all active component service members with an incident diagnosis of glaucoma during the period between 2013 and 2017. The analysis identified 37,718 incident cases of glaucoma and an overall incidence rate of 5.9 cases per 1,000 person-years (p-yrs). The majority of cases (97.6%) were diagnosed at an early stage as borderline glaucoma; of these borderline cases, 2.2% progressed to open-angle glaucoma during the study period. No incident cases of absolute glaucoma, or total blindness, were identified. Rates of glaucoma were higher among non-Hispanic black (11.0 per 1,000 p-yrs), Asian/Pacific Islander (9.5), and Hispanic (6.9) service members, compared with non-Hispanic white (4.0) service members. Rates among female service members (6.6 per 1,000 p-yrs) were higher than those among male service members (5.8). Between 2013 and 2017, incidence rates of glaucoma diagnoses increased by 75.4% among all service members.

Re-evaluation of the MSMR Case Definition for Incident Cases of Malaria

Article
2/1/2019
Anopheles merus

The MSMR has been publishing the results of surveillance studies of malaria since 1995. The standard MSMR case definition uses Medical Event Reports and records of hospitalizations in counting cases of malaria. This report summarizes the performance of the standard MSMR case definition in estimating incident cases of malaria from 2015 through 2017. Also explored was the potential surveillance value of including outpatient encounters with diagnoses of malaria or positive laboratory tests for malaria in the case definition. The study corroborated the relative accuracy of the MSMR case definition in estimating malaria incidence and provided the basis for updating the case definition in 2019 to include positive laboratory tests for malaria antigen within 30 days of an outpatient diagnosis.

Outbreak of Acute Respiratory Illness Associated with Adenovirus Type 4 at the U.S. Naval Academy, 2016

Article
2/1/2019
Malaria case definition

Human adenoviruses (HAdVs) are known to cause respiratory illness outbreaks at basic military training (BMT) sites. HAdV type-4 and -7 vaccines are routinely administered at enlisted BMT sites, but not at military academies. During Aug.–Sept. 2016, U.S. Naval Academy clinical staff noted an increase in students presenting with acute respiratory illness (ARI). An investigation was conducted to determine the extent and cause of the outbreak. During 22 Aug.–11 Sept. 2016, 652 clinic visits for ARI were identified using electronic health records. HAdV-4 was confirmed by real-time polymerase chain reaction assay in 18 out of 33 patient specimens collected and 1 additional HAdV case was detected from hospital records. Two HAdV-4 positive patients were treated for pneumonia including 1 hospitalized patient. Molecular analysis of 4 HAdV-4 isolates identified genome type 4a1, which is considered vaccine-preventable. Understanding the impact of HAdV in congregate settings other than enlisted BMT sites is necessary to inform discussions regarding future HAdV vaccine strategy.

Page 14 of 15 , showing items 196 - 210
First < ... 11 12 13 14 15 > Last 
Refine your search
Last Updated: October 26, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery